肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
Cancer Research and Clinic
2015年
10期
690-693
,共4页
食管肿瘤%放射疗法%贫血%预后
食管腫瘤%放射療法%貧血%預後
식관종류%방사요법%빈혈%예후
Esophageal neoplasms%Radiotherapy%Anemia%Prognosis
目的 了解食管癌患者贫血状况并探讨放疗前贫血对食管癌患者预后的影响.方法 回顾性分析386例食管癌患者放疗前后血红蛋白(Hh)水平,比较放疗前贫血组与正常组放疗后1、3、5年生存率,分析贫血对患者预后的影响以及与其他临床因素的相关性.结果 386例患者中,放疗前贫血患者179例(46.3％),血红蛋白(Hb)49 ～ 169 g/L(中位值116g/L);放疗后贫血患者286例(74.2％),Hb45～ 152g/L(中位值98g/L).放疗前后食管癌患者贫血发生率比较,差异有统计学意义(x2=61.915,P＜ 0.001).食管癌患者肿瘤分期越晚、Kamofky评分越低、体质量指数(BMI)越低、治疗前体质量下降越多,贫血发生率越高(P＜0.05).放疗前贫血组中位生存期为42个月,正常组为52个月,两组差异有统计学意义(x2=5.002,P=0.025).放疗前贫血组中未接受治疗者占87.7％.结论 食管癌放疗患者放疗前后的贫血发生情况均较严重,放疗前贫血可导致食管癌患者生存率降低,应及时纠正患者贫血以提高生存率.
目的 瞭解食管癌患者貧血狀況併探討放療前貧血對食管癌患者預後的影響.方法 迴顧性分析386例食管癌患者放療前後血紅蛋白(Hh)水平,比較放療前貧血組與正常組放療後1、3、5年生存率,分析貧血對患者預後的影響以及與其他臨床因素的相關性.結果 386例患者中,放療前貧血患者179例(46.3％),血紅蛋白(Hb)49 ～ 169 g/L(中位值116g/L);放療後貧血患者286例(74.2％),Hb45～ 152g/L(中位值98g/L).放療前後食管癌患者貧血髮生率比較,差異有統計學意義(x2=61.915,P＜ 0.001).食管癌患者腫瘤分期越晚、Kamofky評分越低、體質量指數(BMI)越低、治療前體質量下降越多,貧血髮生率越高(P＜0.05).放療前貧血組中位生存期為42箇月,正常組為52箇月,兩組差異有統計學意義(x2=5.002,P=0.025).放療前貧血組中未接受治療者佔87.7％.結論 食管癌放療患者放療前後的貧血髮生情況均較嚴重,放療前貧血可導緻食管癌患者生存率降低,應及時糾正患者貧血以提高生存率.
목적 료해식관암환자빈혈상황병탐토방료전빈혈대식관암환자예후적영향.방법 회고성분석386례식관암환자방료전후혈홍단백(Hh)수평,비교방료전빈혈조여정상조방료후1、3、5년생존솔,분석빈혈대환자예후적영향이급여기타림상인소적상관성.결과 386례환자중,방료전빈혈환자179례(46.3％),혈홍단백(Hb)49 ～ 169 g/L(중위치116g/L);방료후빈혈환자286례(74.2％),Hb45～ 152g/L(중위치98g/L).방료전후식관암환자빈혈발생솔비교,차이유통계학의의(x2=61.915,P＜ 0.001).식관암환자종류분기월만、Kamofky평분월저、체질량지수(BMI)월저、치료전체질량하강월다,빈혈발생솔월고(P＜0.05).방료전빈혈조중위생존기위42개월,정상조위52개월,량조차이유통계학의의(x2=5.002,P=0.025).방료전빈혈조중미접수치료자점87.7％.결론 식관암방료환자방료전후적빈혈발생정황균교엄중,방료전빈혈가도치식관암환자생존솔강저,응급시규정환자빈혈이제고생존솔.
Objective To investigate the incidence of anemia among patients with esophageal carcinoma undergoing radiotherapy, and to explore its influence on prognosis.Methods The data of 386 patients with esophageal carcinoma undergoing radiotherapy were collected retrospectively.The survival rates of the 1st, 3rd, 5th year were compared between the anemia group and non-anemia group.Analysis was carried on the impact factors of amenia on the prognosis and other clinical factors.Results The incidence of anemia before radiotherapy was 46.3 ％ (179/386), and the level of hemoglobin was 116 g/L (49-169 g/L).The incidence of anemia after radiotherapy was 74.2 ％ (286/386), and the level of hemoglobin was 98 g/L (45-152 g/L).The incidences of anemia between before and after radiotherapy were statistically different (x2 =61.915, P ＜ 0.001).The incidence of anemia before radiotherapy was associated with stage, Karnofsky score, BMI and the weight loss before treatment (P ＜ 0.05).The median survival time of the anemia group was 42 months, while that of the non-anemia group was 52 months, and the difference was statistically significant (x2 =5.002, P =0.025).There were 87.7 ％ of anemia patients got no treatment.Conclusions The prevalences of anemia before and after radiotherapy are high, and anemia before radiotherapy can decrease the survival rate in esophageal carcinoma patients.Methods should be taken to improve the haemoglobin level in order to increase the survival rate.
